blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2687608

EP2687608 - Methods for the identification, assessment, and treatment of patients with cancer therapy [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.12.2017
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  06.01.2017
FormerGrant of patent is intended
Status updated on  23.12.2016
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139 / US
[2014/04]
Inventor(s)01 / Bryant, Barbara
116 Henry Street
Cambridge, MA 02139 / US
02 / Damokosh, Andrew
115 Waterside Lane
West Hartford, CT 06107 / US
03 / Mulligan, George
32 Taft Avenue
Lexington, MA 02421 / US
 [2017/06]
Former [2014/04]01 / Bryant, Barbara
116 Henry Street
Cambridge, MA Massachusetts 02139 / US
02 / Damokosh, Andrew
115 Waterside Lane
West Hartford, CT Connecticut 06107 / US
03 / Mulligan, George
32 Taft Avenue
Lexington, MA Massachusetts 02421 / US
Representative(s)HGF
HGF Limited
Mill House
North Street
York YO1 6JD / GB
[N/P]
Former [2017/06]Taylor, Kate Laura
HGF Limited
Saviour House
9 St Saviourgate
York YO1 8NQ / GB
Former [2014/04]Taylor, Kate Laura
Harrison Goddard Foote LLP
Saviour House
9 St Saviourgate
York YO1 8NQ / GB
Application number, filing date13181515.108.06.2006
[2014/04]
Priority number, dateUS20050688634P08.06.2005         Original published format: US 688634 P
[2014/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2687608
Date:22.01.2014
Language:EN
[2014/04]
Type: B1 Patent specification 
No.:EP2687608
Date:08.02.2017
Language:EN
[2017/06]
Search report(s)(Supplementary) European search report - dispatched on:EP02.01.2014
ClassificationIPC:C12Q1/68
[2014/04]
CPC:
C12Q1/6886 (EP,US); A61K31/69 (EP,US); A61P35/00 (EP);
A61P35/02 (EP); G01N33/57407 (EP,US); G01N33/57415 (EP,US);
G01N33/57419 (EP,US); G01N33/57423 (EP,US); G01N33/57426 (US);
G01N33/57434 (EP,US); G01N33/57438 (EP,US); G01N33/57449 (EP,US);
G06Q20/40 (US); G16B25/00 (EP,US); G16B25/10 (EP,US);
G16B40/10 (EP,US); G16H10/40 (EP,US); G16H20/40 (EP,US);
C12Q2600/106 (EP,US); C12Q2600/136 (EP,US); C12Q2600/158 (US);
G01N2800/44 (EP,US); G16B40/00 (EP,US); Y02A90/10 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2014/04]
Extension statesRS23.08.2013
TitleGerman:Verfahren zur Identifikation, Beurteilung und Behandlung von Patienten mit Krebstherapie[2014/04]
English:Methods for the identification, assessment, and treatment of patients with cancer therapy[2014/04]
French:Procédés pour l'identification, l'évaluation et le traitement de patients suivant une cancérothérapie[2014/04]
Examination procedure23.08.2013Examination requested  [2014/04]
22.07.2014Amendment by applicant (claims and/or description)
11.05.2015Despatch of a communication from the examining division (Time limit: M06)
19.11.2015Reply to a communication from the examining division
22.08.2016Communication of intention to grant the patent
21.12.2016Fee for grant paid
21.12.2016Fee for publishing/printing paid
21.12.2016Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06784710.3  / EP1899486
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060784710) is  24.08.2011
Opposition(s)09.11.2017No opposition filed within time limit [2018/03]
Fees paidRenewal fee
23.08.2013Renewal fee patent year 03
23.08.2013Renewal fee patent year 04
23.08.2013Renewal fee patent year 05
23.08.2013Renewal fee patent year 06
23.08.2013Renewal fee patent year 07
23.08.2013Renewal fee patent year 08
30.06.2014Renewal fee patent year 09
29.06.2015Renewal fee patent year 10
27.06.2016Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.06.2006
AT08.02.2017
CY08.02.2017
CZ08.02.2017
DK08.02.2017
EE08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
MC08.02.2017
NL08.02.2017
PL08.02.2017
RO08.02.2017
SE08.02.2017
SI08.02.2017
SK08.02.2017
TR08.02.2017
BG08.05.2017
GR09.05.2017
IE08.06.2017
IS08.06.2017
LU08.06.2017
PT08.06.2017
CH30.06.2017
LI30.06.2017
[2020/33]
Former [2020/15]HU08.06.2006
AT08.02.2017
CY08.02.2017
CZ08.02.2017
DK08.02.2017
EE08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
MC08.02.2017
NL08.02.2017
PL08.02.2017
RO08.02.2017
SE08.02.2017
SI08.02.2017
SK08.02.2017
TR08.02.2017
BG08.05.2017
GR09.05.2017
IE08.06.2017
LU08.06.2017
PT08.06.2017
CH30.06.2017
LI30.06.2017
Former [2019/46]HU08.06.2006
AT08.02.2017
CY08.02.2017
CZ08.02.2017
DK08.02.2017
EE08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
MC08.02.2017
NL08.02.2017
PL08.02.2017
RO08.02.2017
SE08.02.2017
SI08.02.2017
SK08.02.2017
BG08.05.2017
GR09.05.2017
IE08.06.2017
LU08.06.2017
PT08.06.2017
CH30.06.2017
LI30.06.2017
Former [2019/31]HU08.06.2006
AT08.02.2017
CZ08.02.2017
DK08.02.2017
EE08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
MC08.02.2017
NL08.02.2017
PL08.02.2017
RO08.02.2017
SE08.02.2017
SI08.02.2017
SK08.02.2017
BG08.05.2017
GR09.05.2017
IE08.06.2017
LU08.06.2017
PT08.06.2017
CH30.06.2017
LI30.06.2017
Former [2018/21]AT08.02.2017
CZ08.02.2017
DK08.02.2017
EE08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
MC08.02.2017
NL08.02.2017
PL08.02.2017
RO08.02.2017
SE08.02.2017
SI08.02.2017
SK08.02.2017
BG08.05.2017
GR09.05.2017
LU08.06.2017
PT08.06.2017
CH30.06.2017
LI30.06.2017
Former [2018/14]AT08.02.2017
CZ08.02.2017
DK08.02.2017
EE08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
MC08.02.2017
NL08.02.2017
PL08.02.2017
RO08.02.2017
SE08.02.2017
SI08.02.2017
SK08.02.2017
BG08.05.2017
GR09.05.2017
PT08.06.2017
Former [2018/11]AT08.02.2017
CZ08.02.2017
DK08.02.2017
EE08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
MC08.02.2017
NL08.02.2017
PL08.02.2017
RO08.02.2017
SE08.02.2017
SK08.02.2017
BG08.05.2017
GR09.05.2017
PT08.06.2017
Former [2017/50]AT08.02.2017
CZ08.02.2017
DK08.02.2017
EE08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
NL08.02.2017
PL08.02.2017
RO08.02.2017
SE08.02.2017
SK08.02.2017
BG08.05.2017
GR09.05.2017
PT08.06.2017
Former [2017/49]AT08.02.2017
CZ08.02.2017
EE08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
NL08.02.2017
RO08.02.2017
SE08.02.2017
SK08.02.2017
BG08.05.2017
GR09.05.2017
PT08.06.2017
Former [2017/48]AT08.02.2017
CZ08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
NL08.02.2017
SE08.02.2017
BG08.05.2017
GR09.05.2017
PT08.06.2017
Former [2017/41]AT08.02.2017
FI08.02.2017
LT08.02.2017
LV08.02.2017
NL08.02.2017
SE08.02.2017
BG08.05.2017
GR09.05.2017
PT08.06.2017
Documents cited:Search[AD]WO2004053066  (MILLENNIUM PHARM INC [US], et al) [AD] 1-16 * abstract * * page 59, paragraph 5 - page 66, paragraph 2; claims 1-26 * * page 69, paragraph 4; tables 1,2 * * page 22, paragraph 3 * * page 60 - page 61; table B *;
 [XA]  - BOHEN SEAN P ET AL, "Variation in gene expression patterns in follicular lymphoma and the response to rituximab", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES - PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 100, no. 4, doi:10.1073/PNAS.0437875100, ISSN 0027-8424, (20030218), pages 1926 - 1930, (20030205), XP002595370 [X] 16 * abstract * [A] 1-15

DOI:   http://dx.doi.org/10.1073/PNAS.0437875100
 [IA]  - B. BARLOGIE, "Treatment of multiple myeloma", BLOOD, (20040101), vol. 103, no. 1, doi:10.1182/blood-2003-04-1045, ISSN 0006-4971, pages 20 - 32, XP055040377 [I] 1-15 * abstract * * page 24, column 2, paragraph 3 * [A] 16

DOI:   http://dx.doi.org/10.1182/blood-2003-04-1045
 [A]  - BARLOW WILLIAM ET AL, "Predicting event-free and overall survival after treatment of myeloma with the proteasome inhibitor Bortezomib with pre-treatment and 48-hour post-therapy gene expression patterns", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20041101), vol. 104, no. 11, Part 1, ISSN 0006-4971, page 414A, XP009129472 [A] 1-16 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.